Replies to post #135398 on NanoViricides Inc. (NNVC)

[arvitar]

"The Company will be unable to proceed with its business plan beyond approximately September 30, 2018, without obtaining additional financing to support its budgeted Research and Development and other costs."

p.28 https://ih.advfn.com/p.php?pid=nmona&article=75750480

The Company does not currently have a license from TheraCour for the VZV area.

p.7 https://ih.advfn.com/p.php?pid=nmona&article=75750480

[arvitar]

Note that on the day of that 2013 PR, NNVC closed at $4.60.

Given the 80% decline since then, and the certainty of further significant decline in the foreseeable future, one wonders how happy Milton is if he's at all concerned about the appreciation of common shares.

Especially in context of the record highs the markets have been enjoying during all that time. You know, that "opportunity cost" thing some folks consider important.

Milton's $5M worth in convertible debentures become due next June. It will be interesting to see how Milton decides to deal with that.